# The Trial of SHR6508 in Secondary Hyperparathyroidism

> **NCT06434961** · PHASE3 · COMPLETED · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 498 (actual)

## Conditions studied

- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** SHR6508 plus oral placebo tablets
- **DRUG:** Cinacalcet plus intravenous placebo

## Key facts

- **NCT ID:** NCT06434961
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-14
- **Primary completion:** 2025-09-29
- **Final completion:** 2025-11-11
- **Target enrollment:** 498 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06434961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06434961, "The Trial of SHR6508 in Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06434961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*